Showing papers on "Meth- published in 1984"
Journal Article•
TL;DR: Substantial increases in the nigral concentration of substance P-like immunoreactivity (SPLI) were observed after subacute administration of the indirect dopamine agonist, methamphetamine (METH, 15 mg/kg every 6 hr; five doses), consistent with the reduction of SPLI levels previously reported in nigral tissue after pharmacological blockade of the nigrostriatal dopaminergic activity.
Abstract: Substantial increases in the nigral concentration of substance P-like immunoreactivity (SPLI) were observed after subacute administration of the indirect dopamine agonist, methamphetamine (METH, 15 mg/kg every 6 hr; five doses). The effect was opposite, and thus consistent, with the reduction of SPLI levels previously reported in nigral tissue after pharmacological blockade of the nigrostriatal dopaminergic activity. In addition, subacute METH treatment increased SPLI concentrations in other structures associated with the basal ganglia, such as the striatum and entopeduncular nucleus, but not in the hypothalamus or dorsal raphe nucleus. Subacute treatment with d-amphetamine exerted METH-like effects on the substance P neurons of the basal ganglia, whereas haloperidol completely antagonized the METH effect. The possibility that monoaminergic systems help mediate the response of the substance P system to subacute METH treatment is examined.
51 citations
Journal Article•
TL;DR: The results suggest that the antiproliferative activity of IFN may only be responsible to a small extent for the therapeutic effect, and that T-cell immunity was involved in the IFN-dependent therapeutic effect in Meth A-bearing mice.
Abstract: Administration of mouse interferon (IF; 0.5 to 1 × 107 reference units/mg protein) inhibited the growth of Meth A and Meth 1 fibrosarcomas, but to a lesser extent, if at all, the growth of Colon 26 adenocarcinoma in BALB/c mice. The in vitro IFN sensitivity of these three tumors was not consistent with the in vivo therapeutic response in mice bearing these tumors under the present experimental conditions; Colon 26, the most sensitive of the three tumors in the in vitro antiproliferation test, did not respond or responded most poorly to IFN therapy; furthermore, Meth A and Meth 1 tumors responded similarly well to IFN therapy, although there was about a 100-fold difference in their in vitro IFN sensitivity. These results as well as the kinetic analysis of IFN concentrations of the serum of Meth A- or Colon 26-bearing mice did not indicate that the antiproliferative activity of IFN was solely responsible for its in vivo therapeutic effect. In contrast, abrogation of T-cell immunity by α mouse thymocyte globulin completely nullified the IFN-dependent therapeutic effect in Meth A-bearing mice. Furthermore, the IFN-dependent therapeutic response in Meth A tumors was much weaker in T-cell-defective BALB/c (nu/nu) mice than that in immunologically competent BALB/c (+/+) mice and was marginal, if present at all, confirming that T-cell immunity was involved in the IFN-dependent therapeutic effect and suggesting that the antiproliferative activity of IFN may only be responsible to a small extent for the therapeutic effect.
13 citations
Patent•
25 Oct 1984
TL;DR: In this paper, a photopolymeriz able epoxy(meth)acrylate resin, which is suitable for use in permanent protection of printed circuits, has been proposed, which has high adhesion and solder resistance.
Abstract: PURPOSE:The titled ink that contains, essential components, a photopolymeriz able epoxy(meth)acrylate resin, a photopolymerizable urethane(meth)acrylate resin, thus being suitable for use in permanent protection of printed circuits, because it has high adhesion and solder resistance. CONSTITUTION:The objective ink is obtained by using (A) a photopolymerizable epoxy(meth)acrylate resin bearing 2 or more terminal (meth)acrylate groups in the molecule, (B) a photopolymerizable urethane(meth)acarylate resin bearing, through urethane bonds, 2 or more terminal (meth)acrylate groups and (C) a photopolymerizable compound of 250-650mol.wt. having a terminal (meth) acarylate group such as alpha-(meth)acryloyl-omega-tetrahydropolyoxypentamethylene car-bonyl compound, preferably at a weight A/B ratio of 50/50-30/70, (A+B)/C of 80/20-60/40.
8 citations
Patent•
26 Jun 1984
TL;DR: In this paper, the titled resin which can form a cured product having excellent surface hardness, high strength and high elongation, prepared by an addition reaction between a hydroxyl group-containing (meth)acrylate and a specified acrylate/diisocyanate adduct, was described.
Abstract: PURPOSE: The titled resin which can form a cured product having excellent surface hardness, high strength and high elongation, prepared by an addition reaction between a hydroxyl group-containing (meth)acrylate and a specified acrylate/diisocyanate adduct. CONSTITUTION: An adduct is formed between 1pt.mol of glycerin mono(meth) acrylate, formed by an addition reaction between glycidol and (meth)acrylic acid, and about 1.1W3pts.mol of an organic diisocyanate (e.g., trimethylhexamethylene diisocyanate). The obtained adduct is reacted with about 1W2mol, per mol of the isocyanato groups in the adduct, of a hydroxyl group-terminated (meth)acrylate [e.g., 2-hydroxyethyl (meth)acrylate] to obtain a urethane (meth) acrylate resin. COPYRIGHT: (C)1986,JPO&Japio
6 citations
Patent•
30 May 1984
TL;DR: In this article, a coating composition, containing a poly[(meth)acryloyloxyalkyl]-(iso) cyanurate, a polymeth)-acrylate, etc of an alkane polyol and a polymerization initiator, and having improved curability and film characteristics, is presented.
Abstract: PURPOSE:A coating composition, containing a poly[(meth)acryloyloxyalkyl](iso) cyanurate, a poly(meth)acrylate, etc of an alkane polyol and a polymerization initiator, and having improved curability and film characteristics CONSTITUTION:A composition containing (A) a poly[(meth)acryloyloxyalkyl](iso) cyanurate of formula I [X , X and X are (meth)acryloyl, H or alkyl among which two or more thereof are (meth)acryloyl; R , R and R are (poly)oxyalkylene] or formula II, (B) 0-1,000ptswt, based on 100ptswt component (A), poly(meth)acrylate of a 2-12C alkane polyol or polyoxyalkylene di(meth)acrylate, and (C) 001-20ptswt, based on 100ptswt total of the components (A) and (B) polymerization initiator USE:Useful for coating thermoplastic resins other than polyolefins and polyesters
3 citations
Patent•
07 Dec 1984
TL;DR: In this article, the goal is to provide a cured urethane poly(meth)acrylate composed of the reaction product of a specific hydroxyl-containing cyclic compound, an organic polyisocyanate and a hydroxyn-containing (meth), and giving a cured product having excellent color, hardness and scratch resistance.
Abstract: PURPOSE:To provide the titled (meth)acrylate composed of the reaction product of a specific hydroxyl-containing cyclic compound, an organic polyisocyanate and a hydroxyl-containing (meth)acrylate compound, and giving a cured product having excellent color, hardness and scratch resistance CONSTITUTION:The objective urethane poly(meth)acrylate is composed of the reaction product of (A) the compound of formula I (R1 is CH3, C2H5 or C3H7) (eg the compound of formula II), (B) an organic polyisocyanate such as isophorone diisocyanate, and (C) the compound of formula III or formula IV (R2 and R3 are H or CH3; n is 1-20) and/or a compound having one or more OH groups and obtained by the esterification of a polyol and (meth)acrylic acid (eg pentaerythritol triacrylate)
3 citations
Patent•
21 Apr 1984
TL;DR: The compound of formula I (R is H or methyl; n is 2-4; m is 1-3) can be improved by copolymerizing with a polymerizable vinyl monomer, such as 4-(2-Methacryloyloxyethoxy)benzoic acid as discussed by the authors.
Abstract: NEW MATERIAL:The compound of formula I (R is H or methyl; n is 2-4; m is 1-3). EXAMPLE:4-(2-Methacryloyloxyethoxy)benzoic acid. USE:Useful for improving the adhesivity of an adhesive, especially for the use in a dental field, by copolymerizing with a polymerizable vinyl monomer. PROCESS:The compound of formula I can be prepared by oxidizing the compound of formula IV which is obtained either by reacting the hydroxyalkyloxyphenyl compound of formula II (A is methyl or -CHO) with (meth)acryloyl halide in the presence of a base or by reacting the haloalkyloxyphenyl compound of formula III(X is halogen) with an alkali metal (meth)acrylate.
2 citations
Patent•
30 Oct 1984
TL;DR: In this paper, the authors proposed to provide the titled rust preventive with fast curing rate, yielding cured films excellent in adhesion to metals, by incorporating a particular compd. free from (meth)acryloyl groups with a radiation curable unsatd.
Abstract: PURPOSE:To provide the titled rust preventive with fast curing rate, yielding cured films excellent in adhesion to metals, by incorporating a particular compd. free from (meth)acryloyl groups with a radiation curable unsatd. compd. having (meth)acryloyl groups. CONSTITUTION:100pts.wt. compd. having one or more (meth)acryloyl groups, per molecule, capable of reacting by radiation (component A) is incorporated with 20-80pts.wt. compd. free from (meth)acryloyl groups, having an acid value of 30-250 and a softening point of 50-150 deg.C, synthesized from carboxylic acid component, alcohol component and/or epoxy component (component B). Radiation-curable compds. such as polyester (meth)acrylates, or epoxy (meth)acrylates may be used as component A and, if necessary, reactive diluents contg. (meth) acryloyl groups can be added to polyfunctional oligomers.
2 citations
Patent•
21 Apr 1984
TL;DR: The compound of formula I (A is -CH3 or -CHO; R is H or -CH 3; B is lower alkylene which may be branched) is a synthetic intermediate of a polymerizable compound useful for the bonding of especially tooth as mentioned in this paper.
Abstract: NEW MATERIAL:The compound of formula I (A is -CH3 or -CHO; R is H or -CH3; B is lower alkylene which may be branched) EXAMPLE:4-(2'-Methacryloyloxyethoxy)benzaldehyde USE:A synthetic intermediate of a polymerizable compound useful for the bonding of especially tooth The compound of formula II which is used as a remedy in dental field can be prepared by oxidizing the compound of formula I with eg Jones reagent, potassium permanganate, etc PROCESS:The compound of formula I can be prepared either by reacting the compound of formula III with (meth)acryloyl halide [eg (meth)acryloyl chloride] in the presence of a base (eg pyridine), or by reacting the compound of formula IV(X is halogen) with a metallic salt of (meth)acrylic acid [eg sodium (meth) acrylate]
1 citations